5/31/2026 at 4:27:12 AM
>Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.It's not a cure or the trial has been running <1 year?
by tjpnz